Alyce Chen

Associate
Languages: Chinese (Mandarin - Fluent)
Areas of Practice

Alyce Chen advises biopharmaceutical, medical device, diagnostics, and other life sciences companies, as well as life sciences investors, on strategic transactions that fund innovation and drive growth, often across borders.

Buyers, sellers, and strategic partners turn to Alyce for counsel on acquisitions, divestitures, joint ventures, and other strategic transactions. She guides clients through every stage of a deal, from structuring and due diligence through negotiation, signing, and closing. Clients know that Alyce’s experience with multinational companies equips her to address the legal and commercial complexity of cross-border transactions.

Alyce also represents emerging companies and investors in venture capital and growth equity financings, from seed and early-stage rounds through later-stage investments. She advises on deal terms, investor rights, and capital structure. Additionally, she counsels clients on general corporate matters, including corporate governance and compliance.

Experience

  • Represented Eli Lilly in its acquisition of Merida Biosciences for up to $2.8 billion.
  • Represented Eli Lilly in its acquisition of Scorpion Therapeutics’ PI3Kα inhibitor program STX-478 for up to $2.5 billion. 
  • Represented Eli Lilly in its acquisition of Ajax Therapeutics for up to $2.3 billion.
  • Represented financial investors such as Bain Capital Life Sciences, LAV, and RTW Investments, and strategic investors such as Eli Lilly, Sanofi, and Pfizer, in investments in U.S. and Asia-Pacific life sciences companies.
  • Represented Everest Medicines in the first cross-border mRNA vaccine equity and collaboration partnership in which an Asia-based biotechnology company received full technology transfer and manufacturing rights to proprietary mRNA technology developed by the licensor.
  • Represented Tiptree and Fortegra in the $1.65 billion sale of Fortegra to DB Insurance, the second-largest non-life insurer in South Korea.
  • Represented Qorvo, a provider of core technologies for radio frequency solutions, in the sale of its United Silicon Carbide subsidiary and the silicon carbide junction field-effect transistor (SiC JFET) technology business to onsemi.
  • Represented HP, Inc. in its pending sale of Plamex and related assets (Mexico, China).
  • Represented various multinational companies, including Eli Lilly, Pfizer, Johnson & Johnson, and FibroGen, in mergers, acquisitions, joint ventures, and divestitures in the Asia-Pacific region.

Areas of Practice